1498 PuraPharm Corp. Ltd. HKEX · Hong Kong

PuraPharm Corp. (1498) news

PuraPharm Corp. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1498, recorded under Hong Kong. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest PuraPharm Corp. news

We have not published a story on PuraPharm Corp. yet. When there is news, it will appear here.

Questions about PuraPharm Corp.

What is the ticker symbol of PuraPharm Corp.?

PuraPharm Corp. Ltd. trades under the ticker 1498 on HKEX.

Where is PuraPharm Corp. listed?

PuraPharm Corp. Ltd. is listed on HKEX.

Which country or territory is PuraPharm Corp. listed under?

Our directory records PuraPharm Corp. Ltd. under Hong Kong.

What does PuraPharm Corp. do?

Our directory classifies PuraPharm Corp. Ltd. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.

What is the ISIN of PuraPharm Corp.?

The ISIN recorded for PuraPharm Corp. Ltd. is KYG7306Y1044.

Does aibio.space cover PuraPharm Corp.?

aibio.space lists PuraPharm Corp. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to PuraPharm Corp.?

Companies in our directory listed in the same country and business area as PuraPharm Corp.: United Laboratories International Holdings, Wai Yuen Tong Medicine Holdings, Pak Fah Yeow International, CPBIO Holding Company, Regencell Bioscience Holdings, Sino Biopharmaceutical.

Investor discussion: PuraPharm Corp.

Members talk about PuraPharm Corp. (1498). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at PuraPharm Corp., newest first. Each line links the filing it comes from.

Apr 30, 2026Financings
Share or debt issue: (I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (II) PROPOSED GRANT OF GENERAL MANDATES TO BUY BACK SHARES AND ISSUE NEW SHARES; (III) AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF THE SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (IV) NOTICE OF ANNUAL GENERAL MEETING. Source
Mar 23, 2026Financings
Share or debt issue: COMPLETION OF ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE. Source
Feb 26, 2026Financings
Share or debt issue: ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE. Source
Oct 30, 2025Financings
Share or debt issue: COMPLETION OF (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE PATENT LICENCE AGREEMENT INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER THE SPECIFIC MANDATE; AND (2) DISCLOSEABLE TRANSACTION IN RELATION TO THE SUBSCRIPTION OF NEW SHARES BY THE SUBSCRIBER UNDER SPECIFIC MANDATE. Source
Oct 24, 2025Financings
Share or debt issue: POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 24 OCTOBER 2025. Source
Oct 2, 2025Financings
Share or debt issue: (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE PATENT LICENCE AGREEMENT INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) SUBSCRIPTION OF NEW SHARES BY THE SUBSCRIBER UNDER SPECIFIC MANDATE; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING. Source
Aug 15, 2025Mergers
Transaction under the Listing Rules: DELAY IN DESPATCH OF CIRCULAR. Source
Jul 25, 2025Mergers
Transaction under the Listing Rules: (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE PATENT LICENCE AGREEMENT INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; AND (2) SUBSCRIPTION OF NEW SHARES BY THE SUBSCRIBER UNDER SPECIFIC MANDATE. Source
Jun 30, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION LAPSE OF DISPOSAL AGREEMENT IN RELATION TO ACCOUNTS RECEIVABLES. Source
Jun 10, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION DISPOSAL OF ACCOUNTS RECEIVABLES. Source
Apr 29, 2025Financings
Share or debt issue: (I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (II) PROPOSED GRANT OF GENERAL MANDATES TO BUY BACK SHARES AND ISSUE NEW SHARES; AND (III) NOTICE OF ANNUAL GENERAL MEETING. Source
Mar 11, 2025Listings
Share consolidation: (1) EFFECTIVE DATE OF THE CAPITAL REDUCTION AND THE SUBDIVISION; (2) REVISED TIMETABLE; AND (3) FREE EXCHANGE OF SHARE CERTIFICATES. Source
Nov 1, 2024Listings
Share consolidation: PROPOSED CAPITAL REDUCTION AND SUBDIVISION OF UNISSUED SHARES. Source

Press releases

Headlines of PuraPharm Corp.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 8, 2026HKEXnews
Notification Letter to Non-registered Shareholders and Request Form
Oct 8, 2026HKEXnews
Notification Letter to Registered Shareholders and Request Form
Oct 8, 2026HKEXnews
NOTICE OF EXTRAORDINARY GENERAL MEETING
Oct 8, 2026HKEXnews
PROPOSED CHANGE OF AUDITOR AND NOTICE OF EXTRAORDINARY GENERAL MEETING
Sep 21, 2026HKEXnews
Notification Letter to Non-registered Shareholders and Request Form - 2026 Interim Report
Sep 21, 2026HKEXnews
Notification Letter to Registered Shareholders and Change Request Form - 2026 Interim Report
Sep 15, 2026HKEXnews
PROPOSED CHANGE OF AUDITOR
Aug 26, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
Jul 17, 2026HKEXnews
CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVES
Jun 25, 2026HKEXnews
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
May 27, 2026HKEXnews
THE SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
May 27, 2026HKEXnews
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 27 MAY 2026
Apr 30, 2026HKEXnews
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Apr 30, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Apr 30, 2026HKEXnews
(I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (II) PROPOSED GRANT OF GENERAL MANDATES TO BUY BACK SHARES AND ISSUE NEW SHARES; (III) AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF THE SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (IV) NOTICE OF ANNUAL GENERAL MEETING
Apr 27, 2026HKEXnews
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, MEMBER OF THE AUDIT COMMITTEE, MEMBER OF THE REMUNERATION COMMITTEE AND MEMBER OF THE NOMINATION COMMITTEE
Apr 23, 2026HKEXnews
Notification Letter to Non-registered Shareholders and Request Form - 2025 Annual Report
Apr 23, 2026HKEXnews
Notification Letter to Registered Shareholders and Change Request Form - 2025 Annual Report
Mar 25, 2026HKEXnews
ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
Mar 23, 2026HKEXnews
COMPLETION OF ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1498 on TradingView.

Listing details

Company: PuraPharm Corp. Ltd.
Ticker: 1498
Listing: HKEX
Country or territory: Hong Kong
Business scope: Biopharma / pharmaceutical profile checked
ISIN: KYG7306Y1044
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction